Nanocarriers for ocular drug delivery: current status and translational opportunity

Author:

Gorantla Srividya1234,Rapalli Vamshi Krishna1234,Waghule Tejashree1234ORCID,Singh Prem Prakash5674,Dubey Sunil Kumar1234ORCID,Saha Ranendra N.12348,Singhvi Gautam1234ORCID

Affiliation:

1. Industrial Research Laboratory

2. Department of Pharmacy

3. Birla Institute of Technology and Science (BITS)

4. India

5. Formulation Development

6. Slayback Pharma India LLP

7. Hyderabad

8. Birla Institute of Technology & Science (BITS)

Abstract

Ocular diseases have a significant effect on vision and quality of life.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Reference164 articles.

1. WHO , https://www.who.int/blindness/causes/priority/en/index1.html , 2018

2. WHO , International Classification of Diseases, 11th Revision (ICD-11) , https://www.who.int/classifications/icd/en/ , 2019

3. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye

4. U.Patel , M.Boucher , L.de Léséleuc and S.Visintini , Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness , Canadian Agency for Drugs and Technologies in Health , 2016

5. ReSure® Sealant – Ocular Therapeutix , https://www.ocutx.com/products/resure-sealant/ , accessed 30 June 2020

Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3